|The TNNI3 n/a (Catalog #MBS2017127) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The FITC-linked Antibody to Troponin I Type 3, Cardiac (TNNI3) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Troponin I Type 3, Cardiac (TNNI3) can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), Western Blot (WB), ELISA.
Western blotting: 1:50-400
Immunocytochemistry in formalin fixed cells: 1:50-500
Immunohistochemistry in formalin fixed frozen section: 1:50-500
Immunohistochemistry in paraffin section: 1:10-100
Enzyme-linked Immunosorbent Assay: 1:100-5000
Optimal working dilutions must be determined by end user. Researchers should empirically determine the suitability of the TNNI3 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the FITC-linked Antibody to Troponin I Type 3, Cardiac (TNNI3) with the following immunoassay(s):
Immunogen: TNNI3, Human
Immunogen Information: Recombinant TNNI3 (Met1~Gly203) with N-terminal His-Tag
expressed in E.coli.
Accession No.: RPA478Hu01. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing TNNI3 are readily searchable from our website. Different antibodies against the same target such as TNNI3 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.